0001651944-22-000057.txt : 20221114 0001651944-22-000057.hdr.sgml : 20221114 20221114162533 ACCESSION NUMBER: 0001651944-22-000057 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221111 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DermTech, Inc. CENTRAL INDEX KEY: 0001651944 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 842870849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38118 FILM NUMBER: 221386127 BUSINESS ADDRESS: STREET 1: 11099 N. TORREY PINES ROAD STREET 2: SUITE 100 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-450-4222 MAIL ADDRESS: STREET 1: 11099 N. TORREY PINES ROAD STREET 2: SUITE 100 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Constellation Alpha Capital Corp. DATE OF NAME CHANGE: 20150827 8-K 1 dmtk-20221111.htm 8-K dmtk-20221111

Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 11, 2022
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
File Number)
(IRS Employer
Identification No.)
11099 N. Torrey Pines Road, Suite 100
La JollaCA 92037
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code (858450-4222
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock,
par value $0.0001 per share
DMTK Nasdaq
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 1.01.    Entry into a Material Definitive Agreement.

As previously disclosed, on July 1, 2021, DermTech, Inc., or the Company, entered into an Office Lease, or the Original Lease Agreement, dated July 1, 2021, with Kilroy Realty, L.P., or the Landlord, with respect to an aggregate of 95,997 rentable square feet, consisting of the entire building located at 12340 El Camino Real, San Diego, California 92130, or the Building. The Original Lease Agreement was subsequently amended by the First Amendment to Office Lease and the Second Amendment to Office Lease, each dated April 22, 2022.

Pursuant to the Original Lease Agreement, tenants of the “Del Mar Corporate Centre II” office project, or the Project, which consists of the Building and the adjacent office building located at 12390 El Camino Real, San Diego, California 92130, or the Adjacent Building, have access to a fitness center, or the Fitness Center, located at the Adjacent Building.

On November 11, 2022, the Company entered into a Third Amendment to Office Lease, or the Third Amendment, dated effective as of October 7, 2022, with the Landlord. Pursuant to the Third Amendment, the Company and the Landlord agreed that beginning January 1, 2023, the Fitness Center shall be used exclusively by another tenant of the Project. As a result, the measurement of the Expansion Premises (as defined in the Second Amendment) will be reduced from 14,085 rentable square feet of space to 13,310 rentable square feet of space, and the Company’s monthly installment of base rent for the Expansion Premises will be reduced as set forth in Schedule 1 of the Third Amendment.

The foregoing summary is qualified in its entirety by reference to the full text of the Third Amendment, a copy of which is filed as Exhibit 10.1 hereto and is incorporated by reference herein.
Item 9.01.    Financial Statements and Exhibits.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 14, 2022By:/s/ Kevin Sun
Name:Kevin Sun
Title:Chief Financial Officer

EX-10.1 2 kilroydelmar-dermtechxthir.htm EX-10.1 Document
Exhibit 10.1
This THIRD AMENDMENT TO OFFICE LEASE ("Third Amendment") is made and entered into as of October 7, 2022 (the “Effective Date”), by and between KILROY REALTY, L.P., a Delaware limited partnership ("Landlord"), and DERMTECH, INC., a Delaware corporation ("Tenant").
R E C I T A L S :
A.    Landlord and Tenant are parties to the Office Lease dated July 1, 2021 (the "Original Lease"), as amended by that certain First Amendment to Office Lease dated April 22, 2022 (the "First Amendment") and that certain Second Amendment to Office Lease dated April 22, 2022 (the "Second Amendment," and together with the Original Lease and First Amendment, the "Lease"), whereby Tenant leases 110,082 rentable (and usable) square feet of space ("Premises") consisting of the entire office building located at 12340 El Camino Real, San Diego, California 92130 ("Building").
B.    Landlord and Tenant desire to enter into this Third Amendment to make certain modifications to the Lease, and in connection therewith, Landlord and Tenant desire to amend the Lease as hereinafter provided.
A G R E E M E N T :
NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
1.Capitalized Terms. All capitalized terms when used herein shall have the same meaning as is given such terms in the Lease unless expressly superseded by the terms of this Third Amendment.
2.No Fitness Center. Notwithstanding anything to the contrary in the Lease, Landlord and Tenant hereby acknowledge and agree that the fitness center located in the 12390 Building shall be used exclusively by another tenant of the Project effective as of January 1, 2023, and accordingly, such fitness center shall thereafter not constitute part of the Project Common Areas.
3.Measurement of Premises due to Reduction in Project Common Area. As a result of such fitness center no longer constituting part of the Project Common Areas, notwithstanding anything to the contrary in the Lease, effective as of January 1, 2023, the measurement of the Expansion Premises (and accordingly, the Building and the Premises) shall be amended such that (a) the Expansion Premises (as defined in the Second Amendment) contains a total of approximately 13,310 rentable (and usable) square feet of space (reduced from 14,085 rentable (and usable) square feet of space as originally stated in the Second Amendment), and (b) accordingly, the Premises and the Building contain a total of approximately 109,307 rentable (and usable) square feet (reduced from 110,082 rentable (and usable) square feet of space as originally stated in the Lease), and (c) in connection with such new measurements, all amounts owning by Tenant under the Lease shall be decreased in connection with such modified rentable (and usable) square feet of the Expansion Premises, Premises and Building. Accordingly, and notwithstanding anything to the contrary contained in the Lease, from and following January 1, 2023, Tenant shall continue to pay monthly installments of Base Rent for the Existing Premises in accordance with the Lease, Tenant shall pay monthly installments of

[Third Amendment]
[DermTech, Inc.]

Base Rent for the Expansion Premises as set forth in Schedule 1 attached hereto, and Tenant's Share of the Project with respect to the entire Premises shall be 59.88%, and Tenant shall otherwise pay Base Rent and Tenant's Share of Direct Expenses with respect to the entire Premises in accordance with the terms of the Lease.
4.Broker. Landlord and Tenant hereby warrant to each other that they have had no dealings with any real estate broker or agent in connection with the negotiation of this Third Amendment other than Cushman & Wakefield (the "Broker"), and that they know of no other real estate broker or agent who is entitled to a commission in connection with this Third Amendment. Each party agrees to indemnify and defend the other party against and hold the other party harmless from and against any and all claims, demands, losses, liabilities, lawsuits, judgments, and costs and expenses (including, without limitation, reasonable attorneys' fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of the indemnifying party's dealings with any real estate broker or agent, other than the Broker, occurring by, through, or under the indemnifying party. The terms of this Section 4 shall survive the expiration or earlier termination of the term of the Lease, as hereby amended.
5.Statutory Disclosure and Related Terms. For purposes of Section 1938(a) of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that Premises have not undergone inspection by a Certified Access Specialist (CASp). The terms and conditions of Section 24.3 of the Original Lease shall continue to apply to the Lease, as hereby amended, with full force and effect as if stated herein in full.
6.Signatures. The parties hereto consent and agree that this Third Amendment may be signed and/or transmitted by facsimile, e-mail of a .pdf document or using electronic signature technology (e.g., via DocuSign or similar electronic signature technology), and that such signed electronic record shall be valid and as effective to bind the party so signing as a paper copy bearing such party’s handwritten signature. The parties further consent and agree that (1) to the extent a party signs this Third Amendment using electronic signature technology, by clicking “SIGN”, such party is signing this Third Amendment electronically, and (2) the electronic signatures appearing on this Third Amendment shall be treated, for purposes of validity, enforceability and admissibility, the same as handwritten signatures.
7.No Further Modification. Except as set forth in this Third Amendment, all of the terms and provisions of the Lease shall apply with respect to the Expansion Premises and shall remain unmodified and in full force and effect.
[signatures follow on next page]

[Third Amendment]
[DermTech, Inc.]

IN WITNESS WHEREOF, this Third Amendment has been executed on November 11, 2022, as of the day and year first above written.

a Delaware limited partnership
By:    Kilroy Realty Corporation,
a Maryland corporation
Its: General Partner
By:    /s/Nelson Ackerly
Nelson Ackerly
Its:    Senior Vice President, Leasing
By:    /s/ Annie Caldwell
Annie Caldwell
Its:    Vice President, Leasing
a Delaware corporation
By:    /s/ John Doback
John Dobak, M.D.
Its:    CEO

[Third Amendment]
[DermTech, Inc.]


Period During
Expansion Term
Monthly Installment of Base Rent
Expansion Commencement Date – December 31, 2022$41,507.56
January 1, 2023 – Last day of Month 12$39,453.81
Months 13 - 24$76,189.41
Months 25 - 36$78,349.62
Months 37 – 48$80,574.64
Months 49 – 60$82,866.41
Months 61 – 72$85,226.93
Months 73 – 84$87,658.27
Months 85 – 96$90,162.55
Months 97 – 108$92,741.96
Months 109 – 120$95,398.75
Months 121 – Lease Expiration Date$98,135.24


[Third Amendment]
[DermTech, Inc.]

EX-101.SCH 3 dmtk-20221111.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 dmtk-20221111_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 dmtk-20221111_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page
Nov. 11, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 11, 2022
Entity Registrant Name DERMTECH, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38118
Entity Tax Identification Number 84-2870849
Entity Address, Address Line One 11099 N. Torrey Pines Road, Suite 100
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code 858
Local Phone Number 450-4222
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock,par value $0.0001 per share
Trading Symbol DMTK
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001651944
XML 7 dmtk-20221111_htm.xml IDEA: XBRL DOCUMENT 0001651944 2022-11-11 2022-11-11 false 0001651944 8-K 2022-11-11 DERMTECH, INC. DE 001-38118 84-2870849 11099 N. Torrey Pines Road, Suite 100 La Jolla CA 92037 858 450-4222 false false false false Common Stock,par value $0.0001 per share DMTK NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "^#;E4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " O@VY5TD8J&^T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OITG50^CFHGA2$%Q0O(5D=C?8-"$9:??M3>MN%]$'\)B9/]]\ M ].9*$U(^)Q"Q$0.\]7D^R%+$S?L0!0E0#8']#K7)3&4YBXDKZD\TQZB-A]Z MCR":YA8\DK::-,S *JY$ICIKI$FH*:03WIH5'S]3O\"L >S1XT 9>,V!J7EB M/$Y]!Q? #"-,/G\7T*[$I?HG=ND .R6G[-;4.([UV"ZYL@.'MZ?'EV7=R@V9 M]&"P_,I.TC'BAITGO[9W]]L'ID0C1,5YQ:^W@DMQ(]OF?7;]X7<1]L&ZG?O' MQF=!U<&ONU!?4$L#!!0 ( "^#;E697)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M+X-N5:TE\HU4! DA !@ !X;"]W;W)KGNIONHMYX:\Q5&B^\[6F/2AU=+!EL=,-V7*$WBR MEBIF!B[5IJ53Q5F8!\51RW/=NU;,1.(,>OF]N1KT9&8BD?"Y(CJ+8Z8.CSR2 M^[Y#G?<;KV*S-?9&:]!+V88ON/DCG2NX:A4JH8AYHH5,B.+KOC.D#X^>;P/R M-_X4?*_/SHD=RDK*K_9B&O8=UQ+QB ?&2C X[/B(1Y%5 HY_3Z).\9LV\/S\ M7?TI'SP,9L4T'\GHBPC-MN]T'!+R-*/LVJ-F3?*AY M-,")Q&9E810\%1!G!B.YXXK,(0&]E@$]>[<5G&(?C['>A=B9W#4)I0WBN9[W M__ 68!0L7L'BY7JW*,O?PY4V"K+U3Q714<&O5K E_*!3%O"^ S6JN=IQ9_#3 M#_3._17ANRWX;C'UP5@&&12D('CGYA,"X1<0_G40_=H'61@4GB1'F0%[Y1M@, N.,Q95@N,YX\OJRG(P^-LAT-FHB M8'<%V-TU8-,DD"J5BED_:)"%@6DC4I&1S!*C#G ,*VEQ\?$$(;PO".^O(7P2 M$2>S+%YQ506":[@NO;GM4-I!>#H%3^<:GB5[(],0JDVL19!/&T*'*W;\&Z]S M[W;\+H+7+?"ZU^ -PQ!6N6Z\GY!G>(]\3BJSB"M2ZG:[9-8D2ZD4/Y Y/-?D M5;*P (3$\=9<\5O I@>#NOK^(W!DQ"^ACZOUQ?RA^O5DI6=@.+&_0W95.L, MR&H!<=E:P+(74-RZE\) UY1K0KV?5[^0!0\RJ+=#)1.N9.L36MS"R.!K(V6* M[%B4@BU+-OSB=UN-T&RX& ]_QYC.M@)7.?TDYFIC9^D#*)BM=9"4 M)96YK1&LJS>O-'H/]^DAK((P7PE/$=M4HN "M2BEU7NX2Y]F:00P"CQ_"BOR MC7SBU?.#2]D*OVO3KN]7D;7.=IAVM_[";%HTB?@:U-SF/?BV.FZ CQ=&IOFF M&PO9KEMWDOSA MR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB M0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!> M@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V& M8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V; MIJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=Y MYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNH MR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \ M& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH M=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z M@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^ M8* \^>Q\ETWLJ.?]74_P$4$L#!!0 M ( "^#;E67BKL

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://dermtech.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports dmtk-20221111.htm dmtk-20221111.xsd dmtk-20221111_lab.xml dmtk-20221111_pre.xml kilroydelmar-dermtechxthir.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dmtk-20221111.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "dmtk-20221111.htm" ] }, "labelLink": { "local": [ "dmtk-20221111_lab.xml" ] }, "presentationLink": { "local": [ "dmtk-20221111_pre.xml" ] }, "schema": { "local": [ "dmtk-20221111.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "dmtk", "nsuri": "http://dermtech.com/20221111", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20221111.htm", "contextRef": "i17169f2edbac414189c0bbac01182613_D20221111-20221111", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://dermtech.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20221111.htm", "contextRef": "i17169f2edbac414189c0bbac01182613_D20221111-20221111", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001651944-22-000057-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001651944-22-000057-xbrl.zip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end